摘要
Abstract
Objective To evaluate the efficacy of thrombolytic therapy with Reteplase (rPA) for In Jection in patients with acute myocardial infarction,and to evaluate its safety.Methods A total of 60 patients received thrombolytic therapy in patients with acute myocardial infarction by experiment,including 30 patients as the experimental group received Reteplase for In Jection thrombolysis treatment,the remaining 30 patients as control group received urokinase thrombolytic therapy,and the clinical differences between the two groups were observed.Results The treatment effect of the experimental group was significantly better than that of the control group:the rate of vascular patency was high,the blood rheology index was closer to the normal level,and the adverse reactions were less.Conclusion Thrombolytic therapy in patients with acute myocardial infarction by Reteplase (rPA) for In Jection,not only can effectively alleviate the patient`s condition,but also reduce the probability of adverse reactions in patientsto a large extent,and this treatment method has great application value in clinic.关键词
重组人组织型纤溶酶原激酶衍生物/急性心肌梗死/溶栓治疗/安全性Key words
reteplase for in jection/acute myocardial infarction/thrombolytic therapy/safety分类
医药卫生
